WorldCom, Inc. (NASDAQ: WCOM) (Price: $0.83) disclosed that it had inappropriately understated its operating expenses by $3.8 billion in the last 15 months. This almost eliminates WorldCom’s entire reported earnings before interest and taxes (“EBIT”) […]
WorldCom, Inc. (NASDAQ: WCOM) (Price: $0.83) admitted that it had inappropriately understated its operating expenses by $3.8 billion in the last 15 months. This effectively eliminates WorldCom’s entire reported earnings before interest and taxes during […]
Pipe Dream or Delayed Gratification? – Newsday
How Pros Take Profit – Smart Money
Research Frontiers continues to battle with a vocal investor group that is working to drive down the stock price. Earlier this month, Manuel Asensio, chief executive of Asensio & Co., sent a letter to Research […]
Tales of the Tape: CIT OK Won’t Stop Tyco’s Volatility – Dow Jones
Yesterday the Chairman of the Senate Committee that funds Medicare released a U.S. Department of Health and Human Services’ Office of Inspector General (“OIG”) report that found Medicare overpays for home monitor blood glucose test […]
Attached is a copy of ###192.gif::our letter dated June 4, 2002 to Research Frontiers Inc.’s ###(NASDAQ: REFR, Price $12.51) Board of Directors. The letter reiterates our position concerning Research Frontiers’ stock and its earnings potential […]
Letter dated June 4, 2002 to Research Frontiers
During the recent year-end conference call PolyMedica told investors that Herbert Denton was leading the company’s response to the “investigation,” which is a U.S. Department of Justice criminal investigation of PolyMedica and certain of its officers. Mr. […]
May 28, 2002 Letter to PolyMedica Corporation
Make the Connection – Diabetic Investor
We believe that a reasonable analysis of PolyMedica Corporation’s (NASDAQ: PLMD, Price: $37.10) financial reporting should take into account the materiality of its existing criminal liability along with the quality of its reported earnings and […]
May 15, 2002 Letter to PolyMedica Corporation
PolyMedica Corporation (NASDAQ: PLMD, Price: $39.38) recently claimed that the Securities and Exchange Commission (“SEC”) has terminated its investigation of the company. The announcement contained a supporting quote by the “Chairman of the Oversight Committee.” […]
Hemispherx Biopharma, Inc. (AMEX: HEB) (Price: $3.97) recently issued a press release titled, “Hemispherx disseminates new clinical data on experimental treatment of multi-drug resistant HIV/AIDS virus.” The press release states that two Hemispherx collaborators evaluated […]
Running a Victory Lap on VeriSign – Real Commentary
PolyMedica Corporation (NASDAQ: PLMD) (Price: $41.95) recently issued a statement representing that it had received a “notice” from the Securities and Exchange Commission (“SEC”) stating that the SEC’s staff had terminated its PolyMedica inquiry. PolyMedica’s […]
Why Didn’t We All Short Enron? – The Journal of Global Financial Markets
Broker is Cleared of Defamation Over Short Selling – The Legal Intelligencer
The Verdict – Barron’s
The 12 person jury in the Philadelphia Court of Common Pleas case titled Hemispherx Biopharma, Inc. v. Asensio & Company, Inc. and Manuel P. Asensio voted 11 to 1 that Asensio & Company, Inc. did […]
The jury commenced its deliberations after lunch yesterday in our case with Hemispherx Biopharma, Inc. (AMEX: HEB) (Price: $3.75) in the Philadelphia Court of Common Pleas. Judge Albert W. Sheppard has ruled through motions in […]
Broken Hearts – Smart Money
Even following the recent [92%] decline in VeriSign’s stock price, famed short-seller Manuel Asensio isn’t declaring victory. The New York investor continues to have a short position […] Peter Loftus, The Wall Street Journal
VeriSign Hopes Its Volatile Stock Finds Stability – The Wall Street Journal
February 1, 2002 The Honorable John J. LaFalce Ranking Member Financial Services Committee 2310 Rayburn House Office Bldg. Washington, DC 20515 Re: A Free Market Fair Plan (“FMFP”) for increasing corporate responsibility. Dear Congressman LaFalce: […]
The American Stock Exchange’s (“AMEX”) failure to delist Hemispherx Biopharma, Inc. (“HEB”)(Price: $3.92), a criminally organized AMEX listed company, led to a congressional investigation. On December 20, 2001 the findings of the AMEX investigation were […]
Today Asensio & Company, Inc. released a 5 page report with 43 exhibits on the ongoing congressional investigation of the American Stock Exchange’s (“AMEX”) listing requirements, which resulted from the AMEX’s failure to de-list Hemispherx […]
Short sellers and panto villains – Financial Times
© Asensio.com. All rights reserved.